

Pursuant to 37 CFR 1.121(b)(1)(iii), a marked up version of the amended text showing the changes made appears herein as Appendix A.

REMARKS


5 Applicants submit a Sequence Listing for the amino acid sequences disclosed in the specification, in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825. Applicant has amended the specification to include the SEQ ID NO. for each sequence in the specification.

CONCLUSION

10 Applicants respectfully submit that the present application complies with 37 C.F.R. §§ 1.821-1.825. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Please apply any charges not covered, or any credits, to Deposit Account 50-0311.

15 Respectfully submitted,



Ivor R. Elvifi, Reg. No. 39,529
Michel Morency, Reg. No. 50,183
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ LEVIN COHN FERRIS GLOVSKY AND
POPEO PC
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 542-6000
Telefax: (617) 542-2241

20

25

Dated: March 14, 2002

Appendix A: marked up versions of amendments to specification showing the changes made

In the Specification:

- On page 5, line 3, after "NH₂", please insert --(SEQ ID NO: 1)--;
- 5 line 4, after "NH₂", please insert --(SEQ ID NO: 2)--;
- line 5, after "NH₂", please insert --(SEQ ID NO: 3)--;
- line 6, after "NH₂", please insert --(SEQ ID NO: 4)--;
- line 7, after "NH₂", please insert --(SEQ ID NO: 5)--.
- 10 Paragraph beginning at page 5, line 8, has been amended as follows:
- Tachypleusins (Tamura, H. et al., 1993, Chem. Pharm. Bul. Tokyo 41, 978-980) denoted T1, T2 and T3 and polyphemusins (Muta, T. 1994, CIBA Found. Sym. 186, 160-174), denoted P1 and P2, for which the sequences are given below, are corresponding peptides isolated from hemolymph from two crabs, *Tachypleus tridentatus* for tachypleusins T1, T2 and T2 and *Limmululs polyphemus*
- 15 for polyphemusins P1 and P2 (SEQ ID NO: 6 and SEQ ID NO: 7 respectively).
- On page 5, line 16, after "NH₂", please insert --(SEQ ID NO: 6)--;
- line 17, after "NH₂", please insert --(SEQ ID NO: 7)--.
- 20 On page 7, line 5, after "(I)", please insert --(SEQ ID NO: 8)--;
- line 9, after "(II)", please insert --(SEQ ID NO: 9)--;
- line 10, after "(III)", please insert --(SEQ ID NO: 10)--.
- On page 9, line 4, after "RGGRLSYSRRRFSTSTGR", please insert --(SEQ ID NO: 11)--;
- 25 line 6, after "RRLSYSRRF", please insert --(SEQ ID NO: 12)--;

APPLICANTS: Clair *et al.*
U.S.A.N.: 09/857,000

line 7, after “rqikiwfqnrrrmkwkk”, please insert --(SEQ ID NO: 13)--.

Table I beginning at page 16, line 1, has been amended as follows:

--

Compound	
No. 1 (Doxo-SynB1)	doxo-CO-(CH ₂) ₂ -CO- RGGRLSYSRRRFSTSTGR (SEQ ID NO: 11)
No. 2	doxo-SMP-3MP- [rqikiwfqnrrrmkwkk] <u>rqikiwfqnrrrmkwkk (SEQ ID NO: 13)</u>

5

On page 29, in Table VII, in compound 4, after “RGGRLSYSRRRFSTSTGR”, please insert --(SEQ ID NO: 11)--.

TRA 1643499v1